Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q68CJ9
UPID:
CR3L3_HUMAN
Alternative names:
Transcription factor CREB-H
Alternative UPACC:
Q68CJ9; B2R7S6; B7ZL69; M0QYW7; Q6ZMC5; Q96TB9
Background:
Cyclic AMP-responsive element-binding protein 3-like protein 3 (CREB-H) is a transcription factor pivotal in endoplasmic reticulum stress response, activating unfolded protein response target genes. It responds to cAMP stimulation, binding to the cAMP response element and box-B element, thus activating transcription. CREB-H plays a significant role in triglyceride metabolism, essential for maintaining normal plasma triglyceride concentrations.
Therapeutic significance:
CREB-H's involvement in Hypertriglyceridemia 2, characterized by elevated plasma triglyceride and cholesterol levels, underscores its therapeutic potential. Targeting CREB-H could lead to innovative treatments for hypertriglyceridemia and related metabolic disorders, offering new hope for patients with these conditions.